Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2017-03-09
Target enrollment:
Participant gender:
Summary
This trial will evaluate the combination treatment of established chemotherapy regimen
mFOLFOX6 with Selinexor, an oral Selective Inhibitor Of Nuclear Export, in patients with
metastatic Colorectal Cancer. The purpose is to determine the maximum tolerated dose (MTD) of
selinexor in combination with mFOLFOX6.